Press Releases for ABPI

Press Releases
Biovest International Announces Reorganization Plan to Maximize Long-Term Shareholder Value, Fully Pay All Creditors and Continue Operations to Commercialize its Drugs and Technologies
Accentia Biopharmaceuticals Announces Reorganization Plan to Maximize Long-Term Shareholder Value, Fully Pay All Creditors and Continue Operations to Commercialize Its Drug Portfolio
Accentia Biopharmaceuticals Announces Pending Delisting from NASDAQ
Biovest and IDIS Announce Agreement to Launch Named-Patient Program for Anti-Cancer Vaccine in Europe
Accentia Biopharmaceuticals to Present at Rodman & Renshaw 10th Annual Healthcare Conference; Company Also Reports On NASDAQ Compliance Plan
Biovest Announces $1.6M in Federal Funding Appropriated for Groundbreaking Cancer Vaccine & Skin/Bone/Tissue Repair Research
Biovest Announces BiovaxID(R) Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%
Accentia Biopharmaceuticals Receives NASDAQ Notice
Accentia Reports Fiscal Third Quarter Financial Results
Biovest Joins in the Formation of the Joint U.S.-Norway Cancer Research Program, a Collaborative Effort with Plans to Present to NCI and the U.S. Military Healthcare System
Biovest Announces Conference Call / Webcast to Discuss Phase 3 BiovaxID(R) Anti-Cancer Vaccine Results
BeaconEquity.com Issues TraderNotes on Active Stocks: MNLU, DELL, WAHCU, RUTH, ABPI, CATS
Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial
Accentia Biopharmaceuticals to Present at the Jefferies Second Annual Healthcare Conference
Accentia Reports on Multiple Sclerosis Study: Revimmune(R) Shows Unprecedented Results in Reducing Disability and Improving Functions
Accentia Biopharmaceuticals Announces $8.5 Million Financing to Advance Key Strategies for SinuNase(TM) and Revimmune(TM)
BeaconEquity.com Issues Trader Notes on BCFT, ABPI, AGU, MCHP, DSCO, AMAT, NVDA, SPLS
Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Accentia Transfers Listing to NASDAQ Capital Market - May 26 2008 10:32PM
Accentia Biopharmaceuticals Reports Fiscal Second Quarter Financial Results - May 27 2008 12:55AM
SinuNase(TM) Fast-Tracked Pivotal Phase 3 Study in Chronic Sinusitis Shows Statistically Significant Objective Evidence of Superiority of SinuNase Over Control Lavage in Severe Cases
Biovest's CEO to Discuss Pending Milestones for its Anti-Cancer Vaccine, BiovaxID(R), on Wall Street TV and at Las Vegas Small Cap Investment Conference
Accentia Biopharmaceuticals Receives NASDAQ Compliance Notice
Aggressive Stock Alert: MIHS! April 18, 2008
BellwetherReport.com Initiates Analyst Coverage on ABPI, CMOS, AVCT and OMTR
Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma
Biovest Media Alert: Baltimore Sun Reports on First Patient Worldwide to be Cured of Sickle Cell Disease Using Revimmune Therapy for Bone Marrow Transplant